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Abstract
Cystic fibrosis-related diabetes (CFRD) is a common complication for patients with 
cystic fibrosis (CF), a disease caused by mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR). The cause of CFRD is unclear, but a commonly observed 
reduction in first-phase insulin secretion suggests defects at the beta cell level. Here we 
aimed to examine alpha and beta cell function in the Cftrtm1EUR/F508del mouse model 
(C57BL/6J), which carries the most common human mutation in CFTR, the F508del 
mutation. CFTR expression, beta cell mass, insulin granule distribution, hormone 
secretion and single cell capacitance changes were evaluated using islets (or beta cells) 
from F508del mice and age-matched wild type (WT) mice aged 7–10 weeks. Granular 
pH was measured with DND-189 fluorescence. Serum glucose, insulin and glucagon 
levels were measured in vivo, and glucose tolerance was assessed using IPGTT. We 
show increased secretion of proinsulin and concomitant reduced secretion of C-peptide 
in islets from F508del mice compared to WT mice. Exocytosis and number of docked 
granules was reduced. We confirmed reduced granular pH by CFTR stimulation. 
We detected decreased pancreatic beta cell area, but unchanged beta cell number. 
Moreover, the F508del mutation caused failure to suppress glucagon secretion leading 
to hyperglucagonemia. In conclusion, F508del mice have beta cell defects resulting in 
(1) reduced number of docked insulin granules and reduced exocytosis and (2) potential 
defective proinsulin cleavage and secretion of immature insulin. These observations 
provide insight into the functional role of CFTR in pancreatic islets and contribute to 
increased understanding of the pathogenesis of CFRD.
Introduction
Cystic fibrosis (CF) is an autosomal recessive disease 
caused by mutations in CFTR encoding the cystic fibrosis 
transmembrane conductance regulator (CFTR). CFTR is 
an anion channel that conducts Cl− and HCO3− and is 
activated by ATP and cAMP (Chen et  al. 2010). Besides 
being an ion channel CFTR is a regulator of other ion 
channels and membrane proteins (Sheppard & Welsh 
1999). The F508del mutation in CFTR is carried by 65–80% 
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of people living with CF (Koivula et  al. 2016). In both 
human and mouse, F508del-CFTR is misprocessed in the 
endoplasmatic reticulum and the channel is subsequently 
degraded. However, a small portion of F508del-CFTR 
escapes degradation and reaches the plasma membrane 
where it has reduced conductivity (Wilke et al. 2011).
Blood glucose abnormalities are common in CF 
and CF-related diabetes (CFRD) is a common secondary 
complication. Acquiring diabetes on the background of 
CF leads to an increased morbidity and mortality, and 
depending on the age-group studied 30–50% of the adult 
patients have CFRD (Brennan et  al. 2004, Dobson et  al. 
2004, de Valk & van der Graaf 2007). Deficient insulin 
secretion, beta cell dysfunction and various degrees of 
insulin resistance characterize CFRD (Hardin et al. 2008, 
Cano Megias et  al. 2015). The pathogenesis in CFRD is 
still not completely understood. Patients with severe 
mutations in CFTR and pancreatic exocrine insufficiency 
are predictors of CFRD but pancreatic sufficient patients 
also acquire CFRD (Wooldridge et al. 2015). The question 
whether CFTR has a functional role in beta cells is not 
without controversy. We and others have shown that 
CFTR is expressed in primary human and rodent islet cells 
(Boom et al. 2007, Edlund et al. 2014, 2017, Guo et al. 2014, 
Huang et  al. 2017). Moreover, single cell transcriptome 
analysis of human islets has revealed that CFTR mRNA 
is expressed in a subset of alpha and beta cells (Blodgett 
et al. 2015, Segerstolpe et al. 2016). However, on the basis 
of the single cell transcriptome analysis, others have 
argued that CFTR is not expressed at a significant level 
in the islet cells and therefore do not contribute to beta 
cell dysfunction in CF and CFRD (Sun et  al. 2017, Hart 
et al. 2018). Instead, it has been suggested that CFRD is 
driven by a combination of beta cell loss, inflammation, 
islet remodeling and general morbidity (Sun et al. 2017, 
Hart et al. 2018). Loss of beta cell mass is implicated in 
CF but not to the extent seen in type 1 diabetes (Moran 
et al. 2010). Moreover, treatment with the CFTR corrector 
Ivacaftor restored beta cell function and insulin secretion 
in CF patients (Bellin et  al. 2013, Kelly et  al. 2019), 
indicating dysfunctional insulin secretion in CFRD.
Animal models resembling human CF have shed 
light on CFRD pathology. The newborn Cftr−/− ferrets 
display reduced first-phase insulin secretion and glucose 
intolerance (Olivier et al. 2012). The CF pigs are born with 
pancreatic inflammation similar to humans. Islet cell 
mass is intact but when challenged with an intravenous 
glucose tolerance test, glucose tolerance is impaired 
with increased proinsulin to insulin secretion ratio 
(Uc et  al. 2015). Increased proinsulin secretion suggests 
impaired processing of insulin and an intrinsic beta cell 
defect. Also pancreatic-insufficient CF patients have 
increased proinsulin to C-peptide secretion both during 
fasting and in glucose-stimulated conditions (Sheikh 
et al. 2017, Nyirjesy et al. 2018). Hence, suggesting that 
insulin processing might be impaired in human CF. 
Insulin maturation within the insulin granule requires 
cleavage of proinsulin by endopeptidases into mature 
insulin and C-peptide, a process that is dependent on an 
acidic intragranular environment (Davidson et al. 1988). 
Acidification of the granule is achieved by simultaneous 
pumping of H+ and Cl− into the granule (Barg et al. 2001). 
Inadequate granular acidification results in an increased 
intragranular proinsulin to mature insulin ratio (Davidson 
et  al. 1988). We have previously shown that CFTR is 
involved in the regulation of exocytosis and insulin 
secretion in human and mouse beta cells (Edlund et  al. 
2014), and we have proposed that CFTR is important for 
insulin granule priming by providing Cl− to the insulin 
granule via granular ClC3.
The Cftrtm1EUR mouse model (van Doorninck et  al. 
1995, French et  al. 1996), here denoted F508del, carries 
the F508del mutation. The F508del mice are essentially 
pancreatic sufficient but have a lower body weight and 
intestinal disease similar to human CF (French et  al. 
1996, Wilke et al. 2011, Fontes et al. 2015). The F508del 
mouse model on a FVB background has reduced beta 
cell mass and increased insulin sensitivity at young age, 
but developed glucose intolerance with increased age 
(Fontes et al. 2015). Here, we have investigated intrinsic 
effects of CFTR in pancreatic islet hormone secretion 
in young F508del mice on a C57BL/6J background. We 
hypothesized that the F508del mutation could impair 
function and/or induce changes in beta cell area. We 
therefore investigated both changes in beta cell area and 
the possibility that the F508del beta cells have defective 
exocytosis and insulin secretion. Finally, we measured islet 
glucagon and somatostatin secretion. The data presented 
highlight the important contribution of CFTR in beta cells 
for functional insulin secretion.
Materials and methods
Animals and tissues
The global Cftrtm1EUR mouse model (C57BL/6J, F12 
backcrosses), heterozygous for the F508del Cftr 
mutation, was obtained from the Erasmus Medical 
Center (Rotterdam, Netherlands) (Wilke et  al. 2011, 
Fontes et  al. 2015). Heterozygous mice were bred and 
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held in isolator cages and fed with standard diet (R36; 
Lactamin AB, Stockholm, Sweden) and water ad libitum 
(Ohlsson et  al. 2008). Offspring was genotyped by PCR 
analysis followed by digestion of the PCR product with 
SspI. The following primer pairs were used: CF-P580: 
5′-GGACGCAAAGAAAGGGATAAG; and CF-P581: 
5′- CACAACACTGACACAAGTAGC. Female and male 
wild type (WT) (weight: 23 ± 0.5 g) and homozygous 
F508del (weight: 20 ± 0.4 g) mice littermates were used in 
experiments. Littermates aged 7–10 weeks were included 
in the studies. In one experiment, we used beta cells from 
C57BL/6J/AKR/CH3 mice. All experiments were performed 
in accordance with ethical statements and regulations 
approved by the ethical committees in Stockholm and 
Lund. Animals were killed by cervical dislocation and 
islets isolated by collagenase (Sigma-Aldrich) digestion.
Immunocytochemistry
Islets were handpicked in Hanks buffer (Sigma-Aldrich), 
dispersed in Ca2+-free buffer, transferred to cell culture 
media (RPMI-1640; SVA, Uppsala, Sweden) supplemented 
with 10 mmol/L glucose, 10 v/v FBS (Sigma-Aldrich), 
100 IU/mL penicillin/streptomycin, 2 mmol/L l-glutamin 
(both from HyClone, South Logan, UT, USA) and incubated 
overnight at 37.5°C, 5% CO2. The cells were fixed in 
paraformaldehyde, and stained as described (Vikman et al. 
2006). Primary antibodies insulin (Millipore) and CFTR 
(MATG1061; RD Biotech, Besançon, France) (Carvalho-
Oliveira et al. 2004) were used. Corresponding secondary 
antibodies (Jackson ImmunoResearch) were detected 
using confocal laser microscopy (Zeiss instruments) and 
analyzed using Zen software as described (De Marinis 
et  al. 2010). The INS1-823/13 beta cell line lack CFTR 
(CtCFTR = undetermined, CtHPRT = 23, CtPPIA = 18, n = 6 
passages) and was used as a negative control for MATG-
1061 specificity (Supplementary Fig.  1A, see section on 
supplementary data given at the end of this article).
Immunohistochemistry and morphometry
Pancreatic sections (5 μm) were deparaffinized and 
hydrated as described elsewhere (Wierup et  al. 2004). 
Sections were incubated with primary antibodies against 
insulin (9003; EuroDiagnostica, Malmö, Sweden), 
glucagon (7811; EuroDiagnostica), somatostatin (sc-7819; 
Santa Cruz Biotechnology) and secondary antibodies 
(Jackson ImmunoResearch). Immunofluorescence was 
examined in an epifluorescence microscope (Olympus 
BX60; Olympus), see example hormone staining in 
Supplementary Fig. 2A. For beta cell mass quantification 
all islets in three different parts of each pancreas 
(minimum 200 µm apart) were assessed in a blinded 
fashion using NIS-Elements software (NIS-Elements 3.1; 
Nikon). Total insulin-, glucagon- or somatostatin-stained 
area and total section area were measured and alpha, beta 
or delta cell mass was calculated as the ratio between the 
two areas. Beta cell number per islet was calculated using 
DAPI as a marker of cell nuclei. All nuclei surrounded by 
insulin staining were regarded as beta cells. An average of 
44 ± 4 islets per animal were analyzed (nWT = 21 pancreatic 
sections from seven mice, nF508del = 21 pancreatic sections 
from seven mice).
Hormone secretion
Freshly isolated islets were dispersed, handpicked and 
stimulated in Krebs buffer supplemented with 1 mmol/L 
glucose, 1 mg/mL albumin for 30 min followed by 
15 min stimulation in 50 mmol/L KCl or 1 h stimulation 
in 1 mmol/L, 2.8 mmol/L or 16.7 mmol/L glucose with 
or without 10 µmol/L forskolin (Sigma-Aldrich) and/or 
50 µmol/L GlyH-101 (Calbiochem) as indicated. After 
stimulation, islets were dissolved in RIPA buffer (50 mmol/L 
TRIS-HCl, 150 mmol/L NaCl, 0.5 mmol/L NaDeoxycholate, 
2 mmol/L EDTA, 50 mmol/L NaF, 1 v/v Triton-X, 0.1 v/v 
SDS (all from Merck) and sonicated. Supernatant and 
dissolved islets were analyzed with RIA using antibodies 
to detect insulin (RI-13K), C-peptide, glucagon (GL-32K; 
all three from Millipore) and somatostatin (Mercodia AB, 
Malmö, Sweden). Secreted proinsulin was analyzed with 
rat/mouse proinsulin ELISA (10-1232-01, Mercodia AB). 
Secretion experiments were performed independently 
on four occasions using islets pooled from 3 to 5 animals 
of each genotype and 3–5 technical replicates with 12 
islets per replicate for each condition (n = 4). Secretion 
experiment in high K+ (50 mM) were performed on islets 
from individual male mice (NWT = 5 mice, NF508del = 5 mice).
Patch-clamp measurements
An EPC-10 amplifier and Patchmaster software (HEKA 
Elektronik, Lambrecht(Pfalz), Germany) were used to 
evoke and record whole-cell currents and changes in 
membrane capacitance in dispersed beta cells as described 
in Eliasson et al. (2003). Mouse beta cells were distinguished 
from alpha and delta cells by the electrophysiological 
properties of the Na+ current inactivation (Gopel et  al. 
2000). The extracellular solution contained the following 
(in mmol/L): 118 NaCl, 20 TEA-Cl, 5.6 KCl, 2.6 CaCl2, 
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1.2 MgCl2, 5 HEPES and 5 Glucose (pH 7.4 NaOH). 
The intracellular solution contained the following (in 
mmol/L): 125 CsOH, 125 l-glutamic acid, 10 CsCl, 10 
NaCl, 1 MgCl2, 5 HEPES, 3 Mg-ATP, 0.05 EGTA and 0.1 
cAMP (pH 7.15 CsOH). All chemicals are from Merck.
Transmission electron microscopy
Islets were fixed in 2.5 % glutaraldehyde and treated 
with osmium (both from Sigma-Aldrich) as described in 
Andersson et al. (2011). Analysis to estimate total number 
of granules as volume density Nv (granules/µm3) and 
number of docked granules as surface density Ns (granules/
µm2) were performed using the diameter of the insulin 
granules (DWT = 272 ± 2.8 nm and DF508del = 272 ± 3.3 nm) 
and an in-house program in MATLAB. A granule was 
considered docked if the center of the granule was within 
150 nm (~D/2) from the plasma membrane (Olofsson 
et al. 2002).
Intragranular pH measurements
Dispersed single cells from C57BL/6J/AKR/CH3 mice 
were plated onto poly-d-lysine-coated glass bottom 
culture dishes and incubated overnight. Before 
experiments, cells were incubated with 1 µM LysoSensor 
green DND-189 (L-7535; Invitrogen; Thermo Fisher) in 
Krebs buffer for 40 min. During experiments, cells were 
perfused at a flow rate of 1 mL/min at 32°C with Krebs 
buffer supplemented with 2.8 mM or 16.7 mM glucose 
and with 10 µM forskolin in the presence or absence 
of 25 µM GlyH-101. Confocal laser microscopy (Zeiss 
instruments) was used to measure DND-189 fluorescence 
(excitation 443 nm; emission 505 nm) and data was 
analyzed using Zen software. To subtract rundown, 
fluorescence was normalized to traces measured at 
2.8 mM glucose alone.
In vivo measurements
Animals were fasted overnight and 1 mg/g glucose in PBS 
was injected intra-peritoneally (maximum 200 µL/animal) 
and blood glucose levels were measured. Venous blood 
was collected from tail-vein of unanesthetized animals. 
Blood glucose levels were measured using Glucometer 
Elite Strips (Bayer) and serum insulin and glucagon levels 
were analyzed with ELISA (Insulin: 10-1247-01, Glucagon: 
10-1281-01; Mercodia AB). Rate of glucose clearance was 
estimated by subtraction of the blood glucose value at 
each time point with the previous blood glucose value 
divided by the time.
Statistical analysis
Data are presented as mean ± s.e.m. of number of animals 
(N) or number of experiments/cells (n). Students t-test and 
ANOVA were used to calculate statistical significance and 
a P < 0.05 value was considered statistically significant.
Results
F508del islets have reduced beta cell mass
We studied CFTR protein expression in dispersed F508del 
and WT beta cells using confocal immunocytochemistry. 
CFTR was detected using the MATG-1061 monoclonal 
antibody; shown to recognize not only CFTR but also 
F508del-CFTR (Carvalho-Oliveira et al. 2004) (Fig. 1A). 
Plasma membrane expression of CFTR in beta cells from 
F508del mice was lower than in WT mice (Fig.  1B), 
which is in accordance with reduced surface expression 
of F508del-CFTR in other tissues (French et  al. 1996). 
The 2D surface area size of individual beta cells 
was ~20% smaller in F508del compared to WT beta 
cells (Fig. 1C).
We next calculated beta cell area from pancreas 
sections immunostained for insulin (Supplementary 
Fig.  2A), since a previous observation in the F508del 
mice suggests that the main reason for reduced insulin 
secretion in these mice is reduced beta cell mass (Fontes 
et  al. 2015). Our calculations confirmed a reduced beta 
cell area in F508del mice (Fig.  1D). However, when 
we counted the number of nuclei as a measurement of 
number of beta cells within the insulin stained area there 
was no difference between F508del and WT mice (Fig. 1E). 
The pancreas weight was similar between the animals 
(Supplementary Fig. 2B). Alpha or delta cell area was not 
different between F508del mice and WT mice (Fig. 1F and 
G, Supplementary Fig. 2A).
F508del beta cells secrete more proinsulin  
and less C-peptide
We asked the question if the Cftr mutation affects beta cell 
function and measured insulin secretion from isolated 
islets. We measured insulin release after 1 h incubation 
in the non-stimulatory (basal) glucose concentration 
1 mmol/L and the stimulatory glucose concentration 
16.7 mmol/L, respectively. CFTR was activated using the 
cAMP-increasing agent forskolin and CFTR function was 
blocked by the CFTR-antagonist GlyH-101. We found 
reduced basal insulin secretion in F508del (Fig.  2A). 
This work is licensed under a Creative Commons 
Attribution 4.0 Unported License.https://doi.org/10.1530/JOE-18-0570
https://joe.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd.
Printed in Great Britain Downloaded from Bioscientifica.com at 05/06/2019 01:15:28PM
via free access
49
Research
A Edlund et al. Islet hormone secretion in a 
cystic fibrosis model
241:1Journal of 
Endocrinology
As expected, addition of forskolin did not affect basal 
insulin secretion in the WT, whereas it slightly enhanced 
basal release in the F508del islets.
In accordance with our previously published data 
(Edlund et  al. 2014), inhibition of CFTR by GlyH-101 
reduced glucose-stimulated insulin secretion in the 
presence of forskolin in WT islets by ~40% (Fig. 2B). We 
have previously demonstrated the specificity of GlyH-101 
for CFTR (Edlund et al. 2017). The specificity was further 
confirmed using INS1-823/13 cells, which do not express 
CFTR (Supplementary Fig.  1A). GlyH-101 did not affect 
glucose and IBMX-stimulated insulin secretion in 
INS1-823/13 cells (Supplementary Fig. 1B).
Glucose-stimulated insulin secretion did not differ 
between F508del islets and WT islets (Fig. 2B). Moreover, 
forskolin elevated glucose-stimulated insulin secretion 
to a larger extent in the F508del islets (Fig.  2B). We 
believe these surprising results are partly due to reduced 
insulin content in F508del islets compared to WT islets 
(Supplementary Fig.  3A), and partly due to the insulin 
RIA which does not discriminate between insulin and 
proinsulin. We therefore measured the secretion of 
proinsulin and C-peptide separately from the same 
samples. Proinsulin secretion from F508del islets was 
markedly increased during cAMP-stimulation (Fig.  2C, 
Supplementary Fig.  3D). Moreover, GlyH-101 increased 
proinsulin secretion from WT islets while having no 
further effect on F508del islets (Fig. 2C). In line with that 
observation, C-peptide secretion was decreased in F508del 
islets (Fig. 2D, Supplementary Fig. 3E).
F508del beta cells have defective exocytosis of insulin 
granules
We have previously suggested that CFTR regulates 
exocytosis in beta cells (Edlund et al. 2014). We therefore 
measured depolarization-induced insulin secretion 
after incubation in 50 mmol/L K+ during 15 min to 
investigate insulin secretion downstream of beta cell 
depolarization. Depolarization-induced insulin secretion 
was reduced by ~30% in F508del islets (Fig. 2E) compared 
to WT. In the simultaneous presence of forskolin the 
reduction was nearly ~40% (Fig. 2E). During this short 
stimulation in the absence of glucose there was no 
difference in proinsulin secretion between F508del and 
WT mouse islets (Fig. 2F).
To examine the effect of CFTR deficiency on exocytosis 
in detail we measured exocytosis in single F508del and 
Figure 1
Morphological investigation of WT and F508del 
islets and beta cells. (A) Representative image of 
CFTR (yellow) and insulin (red) localization using 
confocal immunocytochemistry in fixed single 
beta cells from a WT and a F508del beta cell. Scale 
bar 5 µm. (B) The ratio of CFTR protein expression 
in the plasma membrane region (P1) compared to 
the cytosol (P2) in WT (n = 14) and F508del (n = 11) 
in insulin positive cells as in (A). (C) Single 2D area 
cell size of insulin positive cells measured on 
confocal images using Zen software. (D) Beta cell 
mass in WT and F508del islets using insulin 
immunohistochemistry. (E) Number of beta cells 
within the insulin stained area in the histology 
sections in (D). (F) Alpha cell mass and (G) delta 
cell mass as in (D). Data are presented as 
mean ± s.e.m., white bar: WT and black bar: 
F508del, *P < 0.05, **P < 0.01. A full color version 
of this figure is available at https://doi.
org/10.1530/JOE-18-0570.
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WT beta cells using standard whole-cell capacitance 
measurements. The increase in membrane capacitance, 
elicited by a train of ten 500-ms depolarizations from 
−70 mV to 0 mV, was significantly reduced in F508del 
beta cells compared to WT beta cells (Fig. 3A, B and C). 
The increase in membrane capacitance evoked by the 
first two depolarizations in the train, reflecting 
ATP-independent exocytosis of primed and pre-docked 
granules (Eliasson et  al. 1997), was reduced by ~50% 
(Fig.  3C). ATP-dependent exocytosis, the latter eight 
depolarizations, was less affected (Fig.  3C). The reduced 
exocytosis was not due to a reduced influx of Ca2+ 
(Supplementary Fig. 4).
Docking of granules is important for functional 
exocytosis and we wanted to confirm that mutations 
in Cftr reduce the docked pool of granules. To this end, 
transmission electron microscopy was employed (Fig. 3D, 
E, F and G). In line with our previous findings in NMRI 
mouse and human beta cells treated with CFTR inhibitors 
(Edlund et  al. 2014), F508del beta cells had a reduced 
surface density (Ns) of granules (Fig.  3F) while the total 
volume density (Nv) was similar between F508del and WT 
beta cells (Fig. 3G).
Cleavage of proinsulin to insulin and C-peptide 
and the process of insulin granular priming require low 
intragranular pH. We therefore measured granular pH 
in mouse beta cells using the fluorescent dye DND-189 
that specifically can be used to measure pH of acidic 
organelles (Fig.  3H and I). We observed a reduction in 
pH after stimulation with 16.7 mM glucose in presence 
of forskolin (in 15/32 cells) in agreement with previous 
measurements (Eliasson et  al. 2003). The reduction was 
reverted in presence of the CFTR-inhibitor GlyH-101.
Forskolin-induced glucagon secretion in the F508del 
mouse is impaired
Recent data show increased glucagon secretion after CFTR 
inhibition in both human and mouse islets, suggesting an 
intrinsic function of CFTR also in alpha cells (Edlund et al. 
2017, Huang et al. 2017). We asked if the CFTR mutation 
would have the same effect and investigated glucagon 
secretion properties in islets from the F508del mice. 
F508del and WT islets were subjected to 1 h-incubation 
in 1 mmol/L glucose to maximally stimulate glucagon 
secretion. Under this condition, F508del islets displayed 
higher glucagon secretion compared to WT islets (Fig. 4A). 
In agreement with previous findings, forskolin caused 
a fourfold amplification of glucagon secretion in WT 
islets (Fig.  4A). Interestingly, the already high level of 
glucagon secretion observed in F508del islets at 1 mmol/L 
glucose alone was not further enhanced by forskolin. At 
16.7 mmol/L glucose, glucagon secretion was elevated in 
F508del islets as compared to WT islets. Glucagon secretion 
from WT islets was (as expected) reduced (Fig. 4B), whereas 
there was no significant difference in glucagon secretion 
from F508del islets as compared to 1 mmol/L glucose.
We have suggested that CFTR regulates electrical 
activity in the alpha cell with a small direct effect 
Figure 2
Insulin, proinsulin and c-peptide secretion from islets isolated from 
F508del and WT mice. (A) Insulin secretion at 1 mmol/L glucose (1 G) and 
cAMP-amplified using 10 µmol/L forskolin (Fsk). CFTR was inhibited using 
50 µmol/L GlyH-101 (GlyH) in WT and F508del islets (nWT = 4, nF508del = 4). (B) 
Insulin secretion at 16.7 mmol/L glucose (16.7 G) and cAMP-amplified 
using forskolin in WT and F508del islets expressed per insulin content. 
CFTR was inhibited using 50 µmol/L GlyH-101 (GlyH, nWT = 4, nF508del = 4). (C) 
Proinsulin secretion per proinsulin content and (D) C-peptide secretion 
measured in the same sample as in (B). (E) Depolarization-induced insulin 
secretion per insulin content in 2.8 mmol/L glucose (2.8 G) and 50 mmol/L 
KCl (K+) with or without 10 µM forskolin (Fsk) in islets from separate mice 
(not pooled, NWT = 5, NF508del = 5). (F) Proinsulin secretion per proinsulin 
content measured in the same samples as in (A). Data are presented as 
mean ± s.e.m., white bar: WT and black bar: F508del, *P < 0.05, **P < 0.01 
WT vs F508del, ‡P < 0.05, ‡‡P < 0.01, ‡‡‡P < 0.001 within WT as compared to 
another condition, †P < 0.05, ††P < 0.01, †††P < 0.001 within F508del as 
compared to another condition.
This work is licensed under a Creative Commons 
Attribution 4.0 Unported License.https://doi.org/10.1530/JOE-18-0570
https://joe.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd.
Printed in Great Britain Downloaded from Bioscientifica.com at 05/06/2019 01:15:28PM
via free access
51
Research
A Edlund et al. Islet hormone secretion in a 
cystic fibrosis model
241:1Journal of 
Endocrinology
on exocytosis in rodent (Edlund et  al. 2017). Here, 
depolarization-induced glucagon secretion was increased 
twofold in F508del islets as compared to WT islets when 
experiments where performed in the presence of forskolin 
(Fig. 4C). The dysregulated glucagon secretion in F508del 
islets was not explained by a difference in glucagon 
content (Fig. 4D).
Impaired somatostatin secretion in the F508del 
mouse
We measured somatostatin secretion and found that it 
was elevated in F508del islets compared to WT islets under 
all glucose conditions (Fig.  4E and F). Normally, cAMP-
increasing agents amplify somatostatin secretion during 
glucose-stimulated conditions (Gerber et  al. 1981, de 
Heer et al. 2008), which was also the case in the WT islets 
(Fig.  4F). Surprisingly, forskolin reduced somatostatin 
secretion in F508del islets during glucose-stimulated 
conditions (Fig. 4F), but increased somatostatin secretion 
from islets stimulated in low glucose (Fig. 4E).
The F508del mouse has improved glucose tolerance 
but reduced glucose clearance
Finally, we investigated glucose homeostasis in the F508del 
mouse in vivo. Fasting blood glucose levels were lower in 
F508del mice as compared to WT mice (Fig. 5A). Serum 
insulin was similar in WT and F508del mice (Fig.  5B), 
while average serum glucagon was three times higher 
in the F508del mice (Fig.  5C). F508del mice subjected 
to an intraperitoneal glucose tolerance test (IPGTT) for 
120 min demonstrated overall lower increases in blood 
glucose levels than the WT mice, when calculated as 
the incremental area under the curve (iAUC) during the 
sampling period (Fig. 5D and E). In the WT mice, an initial 
glucose peak (after ~10 min) was followed by a continuous 
and significant lowering of blood glucose levels reaching 
the levels of the fasting state after 120 min, whereas in the 
F508del mice blood glucose remained similarly elevated 
during the first 30 min of the glucose challenge (Fig. 5D). 
We used the data measured during the IPGTT to calculate 
glucose clearance (Fig. 5F). Glucose clearance was delayed 
Figure 3
Exocytosis of insulin containing granules in WT and F508del beta cells. (A) Membrane capacitance increase during a train of ten 500-ms depolarizations 
from −70 mV to 0 mV in a single beta cell from WT mice. (B) As in (A) but on a single F508del beta cell. (C) Summary of the total increase in membrane 
capacitance from all experiments (Σall, nWT = 16, nF508del = 16) as in (A) and (B), during the first two depolarizations (Σ1–2) and during the latter eight 
depolarizations (Σ3–8). (D) A transmission electron microscopic micrograph of a single beta cell in a WT islet. The plasma membrane is indicated with a solid 
black line and N = nucleus. (E) As in (D) but in an F508del islet. (F) An estimation of the number of large dense core vesicles (LDCV) docked at the plasma 
membrane measured as surface density (NS) (nWT = 28 beta cells from two mice, nF508del = 33 beta cells from two mice). (G) An estimation of the total amount 
of vesicles measured as LDCV volume density (Nv) (nWT = 28 beta cells from two mice, nF508del = 33 beta cells from two mice). Data are presented as 
mean ± s.e.m., white bar: WT and black bar: F508del, *P < 0.05, **P < 0.01 WT vs F508del, ‡‡‡P < 0.001 within WT compared to another condition, †P < 0.05, 
†††P < 0.001 within F508del as compared to another condition. (H) Typical experiments measuring pH as the fluorescence of the probe DND-189 in the 
absence and presence of GlyH-101(GlyH) as indicated. DND-189 fluorescence increase with reduced pH. For clarity we present the inverse fluorescence 
([(Fi/F0)/Fc]−1) so that traces goes below baseline for reduced pH and increases when the pH increases as indicated. Lowering of granular pH was achieved 
by addition of 16.7 mM glucose (G) in presence of 10 µM forskolin (Fsk). The traces were normalized to recordings performed in presence of 2.8 mM 
glucose alone. (I) Summary of results performed as in (H). Data are presented as s.e.m. ± s.d. (nCtrl = 15 cells, nGlyH = 54 cells from N = 3 mice).
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in F508del mice and blood glucose did not return to the 
fasted state in the F508del animals within the sampling 
period (Fig. 5D).
Discussion
We show that exocytosis is defective in F508del beta cells 
together with reduced number of docked insulin granules 
at the plasma membrane. This is in agreement with our 
previously published data (Edlund et  al. 2014), which 
showed involvement of CFTR in human insulin secretion 
and beta cell exocytosis. Moreover, we present evidence 
suggesting that F508del mice have a defective processing 
and maturation of insulin, manifested as increased 
proinsulin secretion and decreased C-peptide secretion 
in forskolin- and glucose-stimulated conditions. Our data 
suggest that the F508del mutation results in an intrinsic 
beta cell defect.
During a glucose challenge, the beta cell release 
insulin in two phases. One rapid first-phase lasting 
10–15 min followed by a slower sustained second-phase 
lasting for hours. Patients with CF have reduced first-
phase insulin secretion (Moran et  al. 1991, Bellin et  al. 
2013). During the IPGTT F508del mice had a lower glucose 
increase in response to the glucose challenge compared to 
WT (Fig. 5D). The F508del is a global transgenic mouse 
with CFTR affected in all cells of the body. The mouse 
most likely have adapted to its genotype, for example a 
leaner body (WT 23 ± 0.5 g NWT = 45 vs F508del 20 ± 0.4 g 
NF508del = 48, P < 0.001; Supplementary Fig. 2B) and lower 
fasting glucose levels compared to WT (Fig.  5A). In the 
IPGTT, the glucose curve is shifted below the WT. Despite 
that, the shape of the curve indicates that F508del have a 
defective glucose handling. It takes 30 min before glucose 
elimination starts, which may reflect a reduced first-phase 
insulin secretion. But as we have not measured insulin 
secretion in vivo we cannot exclude that the defective 
glucose handling is due to peripheral insulin resistance. 
However, in vivo measurements in the Cftrtm1Eur/F508del 
mice on FVB background indicate that these mice have 
increased insulin sensitivity at 11  week and increased 
insulin resistance at week 24 (Fontes et  al. 2015) 
favoring that the defective glucose handling is coupled 
to impaired insulin secretion in our study (with 8-week-
old mice). Indeed, we observe reduced insulin secretion 
in vitro in F508del mice. It is possible that the defective 
insulin secretion observed when studying F508del islets 
on C57BL/6J background in vitro are not detected in vivo 
due to the leaner phenotype causing increased peripheral 
insulin sensitivity (Backhed et al. 2004, Fontes et al. 2015).
Figure 4
Glucagon and somatostatin secretion from isolated F508del and WT 
islets. (A) Glucagon secretion at 1 mmol/L glucose (1G) and cAMP-
amplified using 10 µmol/L forskolin (Fsk) in WT islets and F508del islets 
(nWT = 4, nF508del = 4). (B) Glucagon secretion at 16.7 mmol/L glucose 
(16.7G) amplified using forskolin in WT and F508del islets (nWT = 4, 
nF508del = 4). (C) Depolarization-induced glucagon secretion in 2.8 mmol/L 
glucose (2.8 G) and 50 mmol/L KCl (K+) with or without 10 µmol/L 
forskolin in islets from separate mice (not pooled, NWT = 5, NF508del = 5). (D) 
Glucagon content in islets from (A) and (B). (E) Somatostatin secretion 
measured at 1 mmol/L glucose and amplified using forskolin in WT islets 
and F508del islets (nWT = 4, nF508del = 4). (F) Somatostatin secretion in 
16.7 mmol/L glucose and in presence or absence of forskolin in WT and 
F508del islets (nWT = 4, nF508del = 4). Data are presented as mean ± s.e.m., 
white bar WT and black bar F508del *P < 0.05, **P < 0.01, ***P < 0.001 WT 
vs F508del, ‡‡P < 0.01, ‡‡‡P < 0.001 within WT as compared to another 
condition, †P < 0.05, ††P < 0.01, †††P < 0.001 within F508del as compared to 
another condition.
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In vitro, first-phase insulin secretion is suggested to be 
manifested by the release of primed granules measured 
after (1) a short (15 min) depolarizing stimulation of the 
islets using, for example, high concentration of K+ or 
(2) stimulation of depolarization-induced exocytosis of 
already primed granules using single-cell patch-clamp 
measurements (Daniel et al. 1999, Olofsson et al. 2002). 
Here, we used these two techniques and found that 
depolarization-induced insulin secretion (Fig.  2E) and 
rapid exocytosis of docked insulin granules were reduced 
in F508del islets (Fig. 3A, B and C), suggesting defective 
first-phase insulin secretion in F508del beta cells. The 
electron microscopy analysis further confirmed a role 
for CFTR in insulin granule docking (Fig. 3F). It has been 
suggested that CFTR regulates the KATP channel at least in 
ferret islets (Sun et al. 2017). Stimulation of the islets with 
high K+ or measurements of exocytosis using patch-clamp 
bypass the KATP channel, that is why the results presented 
here cannot be explained by direct involvement of the 
KATP channel.
The functional importance of CFTR in beta cells 
has been questioned (Sun et  al. 2017, Hart et  al. 2018). 
Single cell transcriptome analysis of human islet cells 
show that CFTR is expressed in a subset of alpha and beta 
cells (Blodgett et al. 2015, Baron et al. 2016, Segerstolpe 
et al. 2016). The single cell transcriptome analyses have 
revealed a transcriptome heterogeneity in the beta cell 
population suggesting that there are different pools of beta 
cells (Baron et al. 2016). Indeed, the presence of specific 
pacemaker beta cells dictating the beta cell response have 
been suggested (Johnston et al. 2016). Hence, in light of 
the transcriptomic analysis and our recent human data 
(Edlund et al. 2014), an important intrinsic functional role 
of CFTR in islet cells, despite relatively low expression, 
cannot be excluded. Our data from young F508del mice 
support an intrinsic beta cell defect by the observed 
defects in docking of granules and reduced exocytosis.
The conversion of proinsulin to insulin and C-peptide 
requires a low pH. H+ are vital for optimal conversion 
(Davidson et al. 1988), and Cl− counteract the electrostatic 
gradient across the granule membrane formed by the 
entry of H+ (Barg et al. 2001). We found that both F508del 
beta cells and inhibition of CFTR in WT islets caused 
an increase in secreted proinsulin (Fig.  2C) during 1 h 
glucose stimulation, whereas the secretion of proinsulin 
was not as affected during short depolarization-induced 
beta cell secretion, where instead the exocytotic response 
was clearly reduced (Fig. 2E and 3A, B and C). Moreover, 
we could measure reduced pH in beta cells when priming 
was stimulated with glucose and cAMP: an effect that was 
counteracted with GlyH-101 (Fig. 3H and I). Thus, these 
data indicate that CFTR is involved in the pH-dependent 
acidification needed for proinsulin conversion and 
priming of granules. Taken together these results suggests 
Figure 5
In vivo insulin, glucagon and glucose 
measurements in WT and F508del mice. (A) 
Fasting glucose level in WT and F508del mice 
(nWT = 10, nF508del = 7). (B) Serum insulin (nWT = 13, 
nF508del = 7) and (C) serum glucagon (nWT = 14, 
nF508del = 13). (D) Glucose response to IPGTT 
(nWT = 10, nF508del = 7). (E) Glucose response during 
IPGTT measured as the incremental AUC (iAUC). 
(F) Glucose clearance (µM/min) during IPGTT 
measured as the linear reduction in blood 
glucose level from the glucose peak at 10 min to 
the final time point at 120 min. Data are 
presented as mean ± s.e.m., WT (black filled dots, 
white bar, dashed line) and F508del (black filled 
squares, black bar, solid line); *P < 0.05, 
**P < 0.01 and ***P < 0.001.
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that dysfunctional CFTR impair insulin secretion through 
(1) impaired docking and priming of insulin granules 
leading to reduced exocytosis measured by short time 
beta cell stimulation and (2) defective insulin maturation 
resulting in reduced release of mature insulin and 
increased release of proinsulin in the later phase of insulin 
secretion. It is tempting to speculate that the defective 
exocytosis stresses the F508del beta cell and contributes 
to the progressive failure seen with age reported by Fontes 
et al. (2015). Moreover, CF patients have been reported to 
have a skewed proinsulin to insulin ratio (Hartling et al. 
1988, Hamdi et al. 1993, Sheikh et al. 2017, Nyirjesy et al. 
2018), which has also been shown in F508del pig (Uc 
et al. 2015). It can be argued that loss of beta cell mass 
or endoplasmatic reticulum stress due to misprocessed 
F508del-CFTR increase proinsulin secretion (Seaquist 
et  al. 1996). However, we found that the reduced beta 
cell area in 7–9-week-old F508del mice was mainly due to 
reduced cell size and not number. Moreover, proinsulin 
content was unchanged between F508del and WT islets 
(Supplementary Fig. 3B), suggesting defects mainly in the 
last step of insulin maturation.
In addition to the reduced beta cell function, loss of 
beta cell mass is implicated in CFRD where the continuous 
inflammation of the exocrine pancreas has been proposed 
to eventually affect the islets (Gibson-Corley et al. 2015). 
A previously reported study shows that the Cftrtm1EUR/
F508del mouse model on a FVB background has reduced 
beta cell mass (Fontes et  al. 2015). We confirmed these 
data using the Cftrtm1eur/F508del mouse model on a 
C57BL/6J background (Fig.  1D). These congruent data 
suggest that the phenotype links to the mutation in 
Cftr and not to the genetic background of the strain to 
which the Cftrtm1eur/F508del was crossed. In addition to 
the previous observation we found that, the number of 
beta cells within each islet was similar between WT and 
F508del mice; suggesting that the reduced beta cell area is 
mainly due to smaller beta cells. Indeed, estimation of the 
beta cell size confirms this notion, and the beta cell area 
was on average ~20% smaller compared to the area in WT 
beta cells (Fig.  1C). From the area, we can estimate the 
beta cell radius (r) to be 5.3 and 4.8 µm in WT and F508del 
beta cells, respectively. Although the volume density of 
granules (Nv) was similar, an estimate of the total number 
of granules (Nv × beta cell volume) suggest that each beta 
cell contains approximately ~13,300 granules and ~10,500 
granules in WT and F508del mice, respectively. Thus, 
F508del beta cells have ~20% less granules than the WT 
beta cells. Indeed, we measured a reduced insulin content 
in F508del islets (Supplementary Fig.  3A). The reduced 
beta cell size might be congenital with obstructed beta cell 
differentiation (Zertal-Zidani et  al. 2013) and reduction 
in insulin granules or changes in cellular osmosis due to 
aberrant Cl− conductance (Miley et al. 1998).
Individuals with CF have dysregulated glucagon 
secretion displayed as postprandial hyperglycemia and 
contradictory failure to suppress glucagon secretion. 
The severity of the latter increases along with worsened 
glucose intolerance (Moran et  al. 1991, Lanng et  al. 
1993, Lanng 2001). Also, glucagon secretion stimulated 
by insulin induced hypoglycemia was decreased in both 
CFRD and CF patients with normal glucose tolerance 
(Moran et  al. 1991). Serum glucagon was threefold 
higher in F508del mice, suggesting signs of defective 
mechanisms to suppress glucagon secretion. Indeed, high 
glucose concentrations failed to suppress in vitro glucagon 
secretion in F508del islets. Interestingly, the amount of 
glucagon secreted (in presence of cAMP) from F508del 
islets during 15 min and 1 h was similar (Fig. 4A, B and 
C), suggesting a lower maximal capacity in F508del alpha 
cells. For longer stimulation, the F508del alpha cells 
reach their full activity already in the presence of low 
glucose alone and addition of forskolin has a minor effect 
on amplification. We recently published that CFTR is 
important for glucagon secretion in human and mouse 
alpha cells (Edlund et  al. 2017). The elevated glucagon 
secretion in F508del islets measured here is in agreement 
with our current hypothesis that CFTR is involved 
in the regulation of alpha cell action potential firing 
(Edlund et  al. 2017), recently also supported by others 
(Huang et al. 2017). Hence, in addition to the defective 
insulin secretion caused by the F508del mutation, our 
data provide insights to why CF patients have defective 
glucagon counter-regulation.
Somatostatin secretion by delta cells was abnormal 
in the F508del islets (Fig.  4E and F). Delta cells release 
somatostatin with increased glucose concentration. 
Somatostatin receptors are present on both alpha and 
beta cells and binding of somatostatin inhibits adenylate 
cyclase, activates inwardly rectifying K+ channels and/or 
inhibits Ca2+ channels (Kailey et al. 2012, Brereton et al. 
2015). Somatostatin is an important paracrine regulator of 
insulin and is believed to prevent over-secretion of insulin 
(Brereton et al. 2015). Glucagon secretion is also inhibited 
by somatostatin (Briant et al. 2018). Presence of CFTR in 
rodent delta cells is unclear. Paracrine effects are likely 
to contribute to the increased somatostatin secretion. 
Glucagon has been shown to stimulate somatostatin 
secretion (Brunicardi et al. 2001). In F508del mice, both 
glucagon and somatostatin secretion is elevated so it is 
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possible that the elevated glucagon secretion stimulates 
somatostatin secretion. Another option is that the 
increased somatostatin secretion in F508del is explained 
by altered function of the beta cell. Recently it was shown 
that depolarization of the beta cells spreads via gap 
junctions to delta cells causing release of somatostatin 
and inhibition of glucagon secretion (Briant et al. 2018). 
Moreover, hormone release in the islets is pulsatile and 
driven by Ca2+ oscillations (Gylfe & Tengholm 2014). 
The oscillations in Ca2+ have been shown to be disrupted 
by inhibition of Cl− influx using DIDS, which instead 
causes a steady increase in Ca2+ (Eberhardson et al. 2000). 
Considering that CFTR is a Cl− channel it is likely that 
mutations in Cftr can cause disruption in Cl− homeostasis 
and disturbances in the intricate paracrine network. 
The exact mechanism of how the paracrine network 
is regulated in F508del mice is not fully elucidated and 
needs further investigation.
Conclusion
Taken together, the F508del mutation in Cftr has 
consequences for alpha and beta cell function in vitro and 
in vivo. The observed defects in the regulation of insulin 
secretion associated with the F508del mutation become 
most apparent during cAMP-dependent stimulation. In 
conclusion, we suggest that presence of F508del mutation 
will cause (1) reduced exocytosis in beta cells, pointing 
toward reduced first-phase insulin secretion, (2) elevated 
release of proinsulin, suggesting defects in the insulin 
maturation process and (3) alpha cell hypersecretion of 
glucagon. Our results provide new insight in CFRD and 
suggest dysfunctional hormone secretion due to alpha 
and beta cell defects as part of the disease mechanism.
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